Hudson Value Partners LLC Sells 39,671 Shares of Azenta, Inc. (NASDAQ:AZTA)

Hudson Value Partners LLC lowered its holdings in Azenta, Inc. (NASDAQ:AZTA - Free Report) by 73.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,390 shares of the company's stock after selling 39,671 shares during the period. Hudson Value Partners LLC's holdings in Azenta were worth $697,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Hantz Financial Services Inc. purchased a new position in shares of Azenta during the 2nd quarter valued at about $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Azenta in the 1st quarter worth approximately $49,000. Farther Finance Advisors LLC lifted its holdings in shares of Azenta by 20.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company's stock worth $74,000 after acquiring an additional 256 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Azenta by 150.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company's stock valued at $84,000 after purchasing an additional 955 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Azenta during the 1st quarter valued at $130,000. Institutional investors own 99.08% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on AZTA shares. Evercore ISI cut their price target on shares of Azenta from $53.00 to $50.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. Needham & Company LLC restated a "buy" rating and set a $69.00 price target on shares of Azenta in a research report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Azenta currently has a consensus rating of "Hold" and a consensus target price of $66.40.

Azenta Price Performance

Azenta stock traded down $0.02 during mid-day trading on Friday, reaching $45.48. 135,091 shares of the company traded hands, compared to its average volume of 492,567. The firm's 50 day moving average price is $46.04 and its 200 day moving average price is $50.79. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -16.19 and a beta of 1.48. Azenta, Inc. has a 52-week low of $40.24 and a 52-week high of $69.16.

Azenta (NASDAQ:AZTA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.09. Azenta had a positive return on equity of 0.89% and a negative net margin of 23.66%. The business had revenue of $173.00 million for the quarter, compared to analysts' expectations of $166.14 million. During the same period in the previous year, the firm posted $0.13 EPS. The business's revenue was up 4.2% on a year-over-year basis. On average, sell-side analysts anticipate that Azenta, Inc. will post 0.33 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Herman Cueto sold 1,595 shares of the stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $43.68, for a total value of $69,669.60. Following the completion of the transaction, the chief financial officer now directly owns 24,604 shares in the company, valued at $1,074,702.72. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.77% of the stock is owned by corporate insiders.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.